文献速递淋巴瘤造血干细胞移植与细胞治疗

循环肿瘤DNA监测改善大B细胞淋巴瘤axi-cel输注后早期复发检测:前瞻性多中心试验结果

Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial.
PubMed 文献 · J Clin Oncol · 2021-06-16

该前瞻性多中心研究评估了循环肿瘤DNA(ctDNA)在复发或难治性大B细胞淋巴瘤患者接受axi-cel治疗前后的预后价值。研究通过新一代测序动态监测ctDNA,发现预处理前ctDNA浓度较高与进展及细胞因子释放综合征/免疫效应细胞相关神经毒性综合征相关,且输注后第28天可检测ctDNA患者的无进展生存和总生存显著更差。

要点

  • 预处理前ctDNA浓度较高与axi-cel输注后进展及CRS/ICANS发生相关。
  • 输注后第28天可检测ctDNA患者的中位PFS为3个月,OS为19个月。
  • ctDNA在94%患者中于影像学复发时或之前被检测到。

核心结论

  • 无创ctDNA评估可对接受axi-cel治疗的大B细胞淋巴瘤患者进行风险分层并预测结局。

研究设计与样本

  • 前瞻性多中心研究,纳入72例接受标准治疗axi-cel的复发或难治性大B细胞淋巴瘤患者。
  • 从开始淋巴细胞清除化疗至进展或axi-cel输注后1年,通过新一代测序频繁监测淋巴瘤特异性VDJ克隆型ctDNA。

主要发现

  • 72例入组患者中69例(96%)成功检测到肿瘤克隆型。
  • 预处理前ctDNA浓度较高与axi-cel输注后进展及发生细胞因子释放综合征和/或免疫效应细胞相关神经毒性综合征相关。
  • 第28天可检测ctDNA患者与不可检测患者的中位无进展生存分别为3个月与未达到(P < .0001),中位总生存分别为19个月与未达到(P = .0080)。
  • 第28天影像学部分缓解或疾病稳定的患者中,同期ctDNA不可检测的10例中1例复发,而同期ctDNA可检测的17例中15例复发(P = .0001)。

临床怎么用

  • ctDNA动态监测可用于axi-cel治疗后早期识别高复发风险患者。
  • 第28天ctDNA状态可辅助影像学评估,尤其在部分缓解或疾病稳定患者中识别潜在复发者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Although the majority of patients with relapsed or refractory large B-cell lymphoma respond to axicabtagene ciloleucel (axi-cel), only a minority of patients have durable remissions. This prospective multicenter study explored the prognostic value of circulating tumor DNA (ctDNA) before and after standard-of-care axi-cel for predicting patient outcomes. METHODS: Lymphoma-specific variable, diversity, and joining gene segments (VDJ) clonotype ctDNA sequences were frequently monitored via next-generation sequencing from the time of starting lymphodepleting chemotherapy until progression or 1 year after axi-cel infusion. We assessed the prognostic value of ctDNA to predict outcomes and axi-cel-related toxicity. RESULTS: A tumor clonotype was successfully detected in 69 of 72 (96%) enrolled patients. Higher pretreatment ctDNA concentrations were associated with progression after axi-cel infusion and developing cytokine release syndrome and/or immune effector cell-associated neurotoxicity syndrome. Twenty-three of 33 (70%) durably responding patients versus 4 of 31 (13%) progressing patients demonstrated nondetectable ctDNA 1 week after axi-cel infusion (P < .0001). At day 28, patients with detectable ctDNA compared with those with undetectable ctDNA had a median progression-free survival and OS of 3 months versus not reached (P < .0001) and 19 months versus not reached (P = .0080), respectively. In patients with a radiographic partial response or stable disease on day 28, 1 of 10 patients with concurrently undetectable ctDNA relapsed; by contrast, 15 of 17 patients with concurrently detectable ctDNA relapsed (P = .0001). ctDNA was detected at or before radiographic relapse in 29 of 30 (94%) patients. All durably responding patients had undetectable ctDNA at or before 3 months after axi-cel infusion. CONCLUSION: Noninvasive ctDNA assessments can risk stratify and predict outcomes of patients undergoing axi-cel for the treatment of large B-cell lymphoma. These results provide a rationale for designing ctDNA-based risk-adaptive chimeric antigen receptor T-cell clinical trials.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Frank MJ, Hossain NM, Bukhari A, et al. Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial. J Clin Oncol. 2021. PMID: 34133196. doi:10.1200/JCO.21.00377

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。